#United States #New York #Pomerantz LLP #NeuroPace #NPCE

Pomerantz Law Firm Investigates NeuroPace, Inc.: An Overview

Pomerantz LLP, a prominent law firm recognized for its expertise in corporate and securities class litigation, has recently announced its investigation into claims on behalf of investors of NeuroPace, Inc. (NASDAQ: NPCE). As revelations surrounding the company's business practices emerge, investors are encouraged to come forward and seek assistance.

Background of NeuroPace

NeuroPace, Inc. is engaged in the development of advanced neuromodulation devices, primarily focusing on treatments for epilepsy. The company’s flagship product, the RNS System, aims to provide innovative solutions for individuals suffering from drug-resistant epilepsy. However, recent developments have raised concerns regarding the company’s operations and disclosures.

The Investigation

As per the announcement made on June 12, 2025, the Pomerantz law firm is probing whether NeuroPace and certain officers or directors have been involved in any form of securities fraud or engaged in unlawful business practices. This follows a press release issued by NeuroPace on May 27, outlining the preliminary results from a critical two-year NAUTILUS study.

The study sought to evaluate the effectiveness and safety of the RNS system for individuals diagnosed with drug-resistant idiopathic generalized epilepsy (IGE). While the company was hopeful for optimistic outcomes, the results revealed a failure to achieve statistical significance for the primary effectiveness endpoint in the overall study population. The press release specified that the study did not demonstrate a significantly longer time to a second generalized tonic-clonic seizure in the active stimulation group compared to the sham stimulation group.

Following the announcement, NeuroPace's stock took a severe hit, dropping $5.02 per share — a staggering 28.39% decline — resulting in a closing price of $12.66 per share on the same day. This sharp drop has drawn attention from both investors and legal practitioners, leading to suspicions regarding the transparency and accuracy of NeuroPace’s communications.

Investors and Legal Implications

In light of these developments, Pomerantz encourages any investors who have lost money due to their investments in NeuroPace to reach out for guidance. This investigation is crucial not only for holding the company accountable but also for ensuring that investors are informed of their rights and options moving forward. The law firm, which has a storied history of class actions, has recovered substantial damages awards for its clients in similar scenarios, demonstrating a robust commitment to fighting for investor rights.

The Legacy of Pomerantz LLP

Founded by Abraham L. Pomerantz, often referred to as the father of class actions, Pomerantz LLP continues to take a leading role in advocating for victims of corporate malpractice. With over 85 years of experience in the field, the firm has a proven track record, including numerous multimillion-dollar settlements for clients affected by securities fraud, breaches of fiduciary duty, and other corporate misconduct. Their dedication to justice remains strong, and they remain proactive in seeking redress for affected investors.

Conclusion

As investigations unfold, those who have invested in NeuroPace should remain vigilant and seek counsel as necessary. The landscape of securities investment is fraught with potential risks, and staying informed is vital. Investors are advised to follow the news surrounding these developments closely and consider reaching out to legal experts like Pomerantz LLP to understand their positions better. For those affected, taking action promptly can be essential in navigating the aftermath of these significant revelations.

For inquiries or to join the class action, investors can contact Danielle Peyton at Pomerantz LLP at [email protected] or via phone at 646-581-9980, ext. 7980.